News

Possible hormonal context for link between raised Lp(a) and VTE

July 20, 2026

Previous research into elevated Lp(a) and venous thromboembolism (VTE) has been inconclusive, but a new study of pre- and post-menopausal women, and men, has suggested a hormonal context for Lp(a)-associated thrombotic risk. In the study of over 240,000 people from UK Biobank, 14% of premenopausal women, 19% of postmenopausal women and 15% of men had […]

Conversion methods for Lp(a) test units compared

July 10, 2026

Expert guidance recommends that Lp(a) test results are reported in the units provided by the laboratory and conversion between units (mg/dL and nmol/L) is avoided, though a conversion factor of 2.5 is commonly used to convert from mg/dL to nmol/L. Now, an analysis of test results in the Lp(a)HORIZON cardiovascular outcomes study has compared the […]

Lp(a) risk variants linked to plaque rupture

May 14, 2026

Two major Lp(a) risk variants (rs10455872 and rs3798220), associated with elevated Lp(a) and increased risk of coronary artery disease, have been linked with plaque rupture, though not with plaque erosion.

Studies support Lp(a) link to high risk plaque

May 8, 2026

Further support for the link between elevated Lp(a) and high risk plaque (HRP) features comes from two recently published studies using coronary computed tomography angiography (CCTA) and validated AI-based algorithms.

Machine learning model could mean fewer Lp(a) tests

April 17, 2026

A machine learning (ML) guided approach to prioritise Lp(a) testing could reduce the number of tests needed to identify individuals with elevated levels. This is the conclusion of researchers who tested an ethnicity-calibrated ML model developed to identify individuals with elevated Lp(a) in UK Biobank.

New US dyslipidaemia guidelines stress importance of Lp(a) measurement

March 17, 2026

Measurement of Lp(a) concentration in all adults at least once for atherosclerotic cardiovascular disease (ASCVD) risk assessment is a key recommendation (COR 1; LOE B-NR) in the new dyslipidaemia guidelines drawn up by the American College of Cardiology and the American Heart Association (ACC/AHA) – the first since 2018.